Dr. Sato

Takami Sato, MD, Ph.D

Contact Dr. Sato

925 Chestnut Street
Suite 320A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis
  2. Co-Targeting HGF/cMET Signaling with MEK Inhibitors in metastatic uveal melanoma
  3. Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma
  4. Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment
  5. Immune check point inhibitors combination in melanoma: Worth the toxicity?
  6. Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization
  7. Yttrium-90 microsphere brachytherapy for liver metastases from uveal melanoma clinical outcomes and the predictive value of fluorodeoxyglucose positron emission tomography
  8. Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells
  9. Paracrine effect of NRG1 and HGF drives resistance to MEK inhibitors in metastatic uveal melanoma
  10. Biology of advanced uveal melanoma and next steps for clinical therapeutics
  11. Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases
  12. Biology of advanced uveal melanoma and next steps for clinical therapeutics
  13. Treatment strategies for clinically detectable metastatic uveal melanoma
  14. Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth
  15. Tumor necrosis factor-α blockade and development of uveal melanoma: Expected adverse effect or just coincidence?
  16. Early arterial stasis during resin-based yttrium-90 radioembolization: Incidence and preliminary outcomes
  17. High-dose vincristine sulfate liposome injection (Marqibo) is not associated with clinically meaningful hematologic toxicity
  18. Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity
  19. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: A randomized clinical trial
  20. The potential role of sunitinib targeting melanomas